CD274 and non-small cell lung carcinoma: Within a multicenter study comprising 63 NSCLC patients possessing a PD-L1 tumor proportion score (TPS) ≥ 50, who were administered first-line Pembrolizumab and fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT), the favorable prognosis group exhibited a median OS of 17.9 months, in contrast to 13.8 and 6.6 months for the intermediate and unfavorable prognosis groups, respectively (74).